Physician profile
Ted Brezel
NPI 1831152115
$5,492.27
in general payments reported to CMS, 2019-2025
27 companies · $1,092 in 2025
The $1,092 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $208 · 2021: $550 · 2022: $899 · 2023: $1,206 · 2024: $671 · 2025: $1,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,835 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,834.86 |
| Education | $133.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $727.67 | 2019-2025 | Skyrizi, Botox |
| Novartis Pharmaceuticals Corporation | $524.62 | 2019-2025 | |
| Lilly USA, LLC | $464.90 | 2019-2024 | Olumiant, Taltz |
| Ucb, INC. | $448.30 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $437.10 | 2019-2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $404.25 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $372.31 | 2019-2025 | Tremfya |
| Allergan, INC. | $328.12 | 2021-2022 | |
| Pfizer INC. | $279.69 | 2019-2025 | |
| Merz North America, INC. | $232.64 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $230.13 | 2019-2025 | Ilumya |
| Amgen INC. | $227.13 | 2022-2024 | Otezla |
| Galderma Laboratories, L.P. | $190.31 | 2020-2025 | Nemluvio |
| Genzyme Corporation | $122.67 | 2019-2025 | |
| Incyte Corporation | $110.70 | 2022-2025 | Opzelura |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $78.60 | 2019-2022 | |
| Botanix Sb INC | $54.88 | 2025 | Sofdra |
| Encore Dermatology INC. | $40.27 | 2019 | |
| Leo Pharma INC. | $38.62 | 2019-2025 | Anzupgo |
| Merck Sharp & Dohme LLC | $33.70 | 2019 | |
| Kyowa Kirin, INC. | $27.45 | 2023 | Poteligeo |
| Verrica Pharmaceuticals INC. | $23.53 | 2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.11 | 2025 | Siliq |
| Arcutis Biotherapeutics, INC. | $19.29 | 2023 | |
| Aclaris Therapeutics, INC. | $18.75 | 2019 | |
| Celgene Corporation | $18.33 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $18.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Brezel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.